Advanced Accelerator Applications 新闻与活动
在场
Advanced Accelerator Applications 的所有者是 Novartis.
是其中之一......
- Forbes Global 2000 (#99);
- Fortune 500 Europe (#62);
- Global Fortune 500 (#263);
- Stoxx 600;
- Swiss market index;
- TOB Iconic 10,000.
Novartis 是一家在股票代码 NOVN (CH) 下上市的公司。
Novartis 在 38 个国家有直接业务。Novartis 拥有 74家子公司，其中包括 Advanced Accelerator Applications、Alcon 和 Alcon ANZ。
他们在：
涉及Novartis的并购和融资。
- Novartis has announced the acquisition of Chinook Therapeutics (公布2023八月14号).
- Novartis has announced the acquisition of DTx Pharma (公布2023七月18号).
- Novartis has announced the acquisition of Chinook Therapeutics (公布2023六月15号).
高管
查看带有其 5 名主要高管的组织结构图
Advanced Accelerator Applications 搜索最多的简介
- Sidonie Golombowski-Daffner, Country President and Pharma General ...
- Jessica Toepfer, Non-Executive Director
- Frederic Collet, Non-Executive Director
高管在Novartis变化
- Karen Hale 曾任 Chief Legal Officer and Member of the Executive Committee, 将于 20254月14 升职为 Chief Legal and Compliance Officer and Member of the Executive Committee (新闻发布的2025三月31号).
- Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, 将于 20254月14 退休 (新闻发布的2025三月31号).
- Haseeb Ahmad, President, Europe, 已经离开公司 (新闻发布的2025三月14号).
创建提醒
跟踪 Advanced Accelerator Applications 的高管变动
药店
Novartis 拥有 1,834 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Eli Lilly (美国(美洲))。
Popular M&A news in 药店
- Imbria Pharmaceuticals 刚刚宣布为 58 筹款数百万美元。 (公布2025四月10号).
- Clario 已收购 NRx Pharmaceuticals (公布2025三月18号).
- Knight Therapeutics has announced the acquisition of Paladin Labs (公布2025三月12号).
药店 行业的其他推荐联系人
消息
Advanced Accelerator Applications 的最新新闻稿
- Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
- Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
- Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
- New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
- Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease
- Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
- Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
- Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
- Novartis ranks first in 2024 Access to Medicine Index
- Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
- View more press releases Close
